Fuji Pharma Co

Fuji Pharma Co EBIT per Share

The EBIT per Share of Fuji Pharma Co (4554.T) as of Oct 18, 2026 is 204.04 JPY. In the previous year, EBIT per Share was 159.56 JPY — a change of 27.87% (higher).

EBIT per Share

204.04JPY

YoY

27.87%

Last updated:

EBIT per Share of Fuji Pharma Co is 2025 204.04 JPY. EBIT per Share of Fuji Pharma Co was 2024 159.56 JPY. It decreases by 27.87% higher compared to the previous year.

The Fuji Pharma Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
158.77 JPY
Jan 1, 2024
159.56 JPY
Jan 1, 2025
204.04 JPY
Jan 1, 2026 (e)
137.19 JPY
Jan 1, 2027 (e)
332.35 JPY
Jan 1, 2028 (e)
368.30 JPY
Jan 1, 2029 (e)
342.01 JPY
Jan 1, 2030 (e)
380.77 JPY
The Fuji Pharma Co EBIT per Share history
YEAREBIT per ShareYoY
est380.77JPY+11.33%
est342.01JPY-7.14%
est368.30JPY+10.82%
est332.35JPY+142.26%
est137.19JPY-32.76%
204.04JPY+27.87%
159.56JPY+0.50%
158.77JPY+2.10%
155.51JPY+11.02%
140.07JPY+38.99%
100.77JPY-24.79%
133.98JPY-9.48%
148.01JPY+1.87%
145.30JPY+21.81%
119.28JPY+9.74%
108.70JPY+7.06%
101.53JPY-12.08%
115.48JPY+18.73%
97.27JPY-22.97%
126.27JPY+0.53%
125.60JPY+31.30%
95.66JPY+19.18%
80.26JPY-0.31%
80.51JPY+37.27%
58.65JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fuji Pharma Co Stock analysis

What does Fuji Pharma Co do? Fuji Pharma Co Ltd is a Japanese company specializing in the healthcare industry. The company was founded in 2001 and is headquartered in Tokyo, Japan. It is listed on the Tokyo Stock Exchange and employs over 1,000 employees. Fuji Pharma's business model is to provide its customers with innovative and high-quality products that contribute to improving health and well-being. The company specializes in several business areas, including the development, manufacturing, and marketing of pharmaceutical products, production of OEM products for other companies, and manufacturing of dietary supplements and cosmetics. An important area for Fuji Pharma is the development and production of pharmaceuticals. The company ensures that its medications meet the highest requirements and international standards. This includes research and development of new products. The company has its own research department specializing in the development of medications that can be used in serious diseases such as cancer, diabetes, and cardiovascular diseases. In addition, Fuji Pharma is also involved in the production of OEM products for other companies. The company ensures the manufacture of medications and medical products for other pharmaceutical companies, meeting the highest quality standards and customer requirements. Fuji Pharma is proud to be a trusted partner for its customers and provides its services according to the requirements of its customers. In addition to these two divisions, Fuji Pharma also produces dietary supplements and cosmetics for the domestic and international markets. These products are designed for consumers who want to improve their health and well-being. The company places great emphasis on the development of natural and safe ingredients for its products and ensures the highest standards of quality and safety. Fuji Pharma has also specialized in the Japanese market for medical devices, particularly in the field of home respiratory devices. The company has developed a new generation of respiratory therapy devices that are safe and easy to use, providing better well-being and quality of life for patients with respiratory diseases. In addition to its business areas, Fuji Pharma also has various products in its portfolio that are known for their quality and effectiveness. One such product is "Efil," a medication used in the treatment of erectile dysfunction disorders. The medication is available in Japan and other Asian countries and has already been used by over 200,000 patients. Fuji Pharma continuously strives to improve its research and development activities and develop new innovative products and services for the healthcare industry. The company aims to bring its products and services to the international market and satisfy its customers in Japan and worldwide. Fuji Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fuji Pharma Co stock

EBIT per Share of Fuji Pharma Co is 204.04 JPY in 2025.

EBIT per Share of Fuji Pharma Co changed from 159.56 JPY to 204.04 JPY, representing a 27.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Fuji Pharma Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fuji Pharma Co

All Key Metrics — Fuji Pharma Co